021-51111890
购物车（）
sales@molnova.cn
BFMO (biogenic Fe-Mn oxides)
CAS No. 69010-90-8
BFMO (biogenic Fe-Mn oxides) ( N,N'-Difurfuryloxamide )
产品货号. M27531 CAS No. 69010-90-8
BFMO (biogenic Fe-Mn oxides, defined as a mixture of biogenic Mn oxide (BMO) and Fe oxide) could eliminate or decrease Fe(II), Mn(II), and As(III&V) species simultaneously.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1855 | 有现货 |
|
| 10MG | ￥3102 | 有现货 |
|
| 25MG | ￥5208 | 有现货 |
|
| 50MG | ￥7412 | 有现货 |
|
| 100MG | ￥10125 | 有现货 |
|
| 500MG | ￥20088 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称BFMO (biogenic Fe-Mn oxides)
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述BFMO (biogenic Fe-Mn oxides, defined as a mixture of biogenic Mn oxide (BMO) and Fe oxide) could eliminate or decrease Fe(II), Mn(II), and As(III&V) species simultaneously.
-
产品描述BFMO (biogenic Fe-Mn oxides, defined as a mixture of biogenic Mn oxide (BMO) and Fe oxide) could eliminate or decrease Fe(II), Mn(II), and As(III&V) species simultaneously. Moreover, BFMO can be used for As removal from water containing high concentrations of Fe(II) and Mn(II).
-
同义词N,N'-Difurfuryloxamide
-
通路Others
-
靶点Other Targets
-
受体β2-adrenergic receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number69010-90-8
-
分子量248.2
-
分子式C12H12N2O4
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESO=C(C(NCc1ccco1)=O)NCc1ccco1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Dimri M, et al. Todralazine protects zebrafish from lethal effects of ionizing radiation: role of hematopoietic cell expansion. Zebrafish. 2015 Feb;12(1):33-47.
产品手册
关联产品
-
HeE1-2Tyr
HeE1-2Tyr, a pyridobenzothiazole compound, is a flavivirus RNA dependent RNA polymerases (RdRp) inhibitor. It significantly inhibits West Nile, Dengue and SARS-CoV-2 RdRps (IC50 of 27.6 μM) activity in vitro.
-
TAT-amide TFA (69722...
TAT-amide TFA is a cell penetrating peptide. The cell - penetrating peptides (CPPs) is a kind of access to the short amino acid sequence of different cells.
-
Thymidylate Kinase I...
YMU1 is a human thymidylate kinase (hTMPK) inhibitor. YMU1 stabilizes the conformation of ligand-induced degradation (LID) region of hTMPK and blocks the catalytic site or ATP-binding site.
